TunisiaTuberculosis profile
Population  2015 11 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.24 (0.049–0.57) 2.1 (0.44–5)
Mortality (HIV+TB only) <0.01 (<0.01–0.013) 0.05 (0.01–0.12)
Incidence  (includes HIV+TB) 4.2 (3.2–5.3) 37 (29–47)
Incidence (HIV+TB only) 0.029 (0.02–0.038) 0.26 (0.18–0.34)
Incidence (MDR/RR-TB)** 0.025 (<0.01–0.043) 0.22 (0.05–0.38)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.23 (0.16–0.29) 1.1 (0.44–1.7) 1.3 (0.61–2)
Males 0.085 (0.054–0.12) 2.8 (2.1–3.5) 2.9 (2.2–3.6)
Total 0.31 (0.22–0.41) 3.9 (3.3–4.4) 4.2 (3.2–5.3)
TB case notifications, 2015  
Total cases notified 3 357
Total new and relapse 3 357
          - % tested with rapid diagnostics at time of diagnosis 7%
          - % with known HIV status 80%
          - % pulmonary 40%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.06 (0.01–0.14)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 15 <1%
          - on antiretroviral therapy 15 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  15
(7–22)
Estimated % of TB cases with MDR/RR-TB 0.54% (0.2–1.2) 17% (7.2–32)  
% notified tested for rifampicin resistance 34% 85% 1 169
MDR/RR-TB cases tested for resistance to second-line drugs   13
Laboratory-confirmed cases MDR/RR-TB: 13, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 13, XDR-TB: 2
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 91% 3 134
Previously treated cases, excluding relapse, registered in 2014 64% 39
HIV-positive TB cases, all types, registered in 2014 100% 12
MDR/RR-TB cases started on second-line treatment in 2013 79% 14
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 11%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 1.4
Funding source: 57% domestic, 43% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data